Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Shengxuening** is an oral traditional Chinese medicine tablet manufactured by Wuhan United Pharmacy for iron deficiency anemia, particularly the traditional Chinese medicine syndrome of qi-and-blood deficiency. It is an extract of silkworm excrement containing sodium iron chlorophyllin and related chlorophyll derivatives. The product provides bioavailable iron for hemoglobin synthesis and has reported hematopoiesis-promoting activity, including stimulation of bone-marrow erythroid progenitor-cell activity. It is an approved Chinese prescription product and protected traditional Chinese medicine variety; additional clinical research has evaluated its use in cancer-related anemia and other anemia settings. ([whlhyy.com.cn](https://www.whlhyy.com.cn/d/file/sxn/yxwx/2017-07-05/938d7b9bfc1f3eb57738733d5ac4e639.pdf))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on shengxuening.